retatrutide dosing phase 2 trial VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide isn't a GLP-1. It's

That means you cannot legitimately place 10.8% for cagrilintide next to 24.2% for retatrutide and declare a winner, because those numbers come from different trials, different populations, different durations (26 vs 48 weeks), different doses, and critically a monotherapy figure for one versus a monotherapy figure for the other, while cagrilintides strongest data are actually as a combination

For example, just under two in five of current users report drinking less alcohol and dining out less since starting a GLP-1 drug

Patient Assistance Programs for Free GLP-1 Medications What this is: Pharmaceutical companies provide free GLP-1 medications through patient assistance programs (PAPs) for people who can't afford them and meet financial requirements

That may include weight loss, improved insulin sensitivity, reduced visceral fat, better cardiometabolic markers, lower inflammatory burden, improved mobility, and greater capacity to exercise

The opportunity could be massive